Seattle Genetics Seeks Adcetris Approval as First-Line Combo Treatment for Peripheral T-cell Lymphomas
News
Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment for patients with ... Read more